Table 4.
Primary reason for sorafenib discontinuation among US patients enrolled in GIDEON
| n (%) | No TACE n=322 | Group A Prior TACE n=160 | Group B Concomitant TACE n=29 | Group C Prior and Concomitant TACE n=38 |
|---|---|---|---|---|
| OLT/other treatment | 4 (1) | 5 (3) | 3 (10) | 2 (5) |
| Progression of liver diseasea | 25 (8) | 12 (8) | 2 (7) | 0 |
| Death | 58 (18) | 18 (11) | 4 (14) | 3 (8) |
| Progression/recurrence/relapse | 72 (22) | 30 (19) | 2 (7) | 8 (21) |
| Adverse event | 42 (13) | 40 (25) | 4 (14) | 2 (5) |
| Otherb | 121 (38) | 55 (34) | 16 (5) | 23 (61) |
Data refer to the enrolled population (n=645).
a
Not tumor progression.
b
Including, but not limited to, deterioration of general condition, lost to follow-up, patient decision, liver transplant. OLT=orthotopic liver transplantation.